{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:17:11Z","timestamp":1789737431159,"version":"4.0.1"},"reference-count":101,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Atherosclerosis remains a leading cause of cardiovascular morbidity and mortality worldwide. While traditionally attributed to lipid accumulation, endothelial dysfunction, and inflammation, growing evidence implicates the lymphatic system as a key regulator of vascular homeostasis and plaque stability. Recent experimental data suggest that restoring lymphatic function may represent a novel therapeutic avenue in atherosclerosis. Recombinant VEGF-C variants and nanoparticle-based gene delivery systems selectively have been shown to induce lymphangiogenesis and improve lipid clearance without triggering abnormal angiogenesis. Similarly, Apolipoprotein A-I infusions have been demonstrated to strengthen lymphatic endothelial junctions, enhance vessel contractility, and facilitate the removal of cholesterol and inflammatory cells from atherosclerotic lesions. This comprehensive review aims to present recent findings from preclinical and clinical trials and studies on investigational pharmacological therapies, explore the interrelationship between atherosclerosis and the lymphatic system, and highlight potential avenues for future research.<\/jats:p>","DOI":"10.3389\/fcvm.2026.1774468","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T05:34:56Z","timestamp":1773812096000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting lymphatic dysfunction in atherosclerosis: a state-of-the-art review on potential therapies and future directions"],"prefix":"10.3389","volume":"13","author":[{"given":"Andrea","family":"Varias-Menor","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Kirk Kerkorian School of Medicine at University of Nevada Las Vegas","place":["Las Vegas, NV, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalise","family":"Michlin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kirk Kerkorian School of Medicine at University of Nevada Las Vegas","place":["Las Vegas, NV, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Stere","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kirk Kerkorian School of Medicine at University of Nevada Las Vegas","place":["Las Vegas, NV, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharif","family":"Afifi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kirk Kerkorian School of Medicine at University of Nevada Las Vegas","place":["Las Vegas, NV, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Tasouli-Drakou","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kirk Kerkorian School of Medicine at University of Nevada Las Vegas","place":["Las Vegas, NV, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Varras","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kirk Kerkorian School of Medicine at University of Nevada Las Vegas","place":["Las Vegas, NV, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"B1","article-title":"Atherosclerosis","volume-title":"StatPearls","author":"Pahwa","year":"2025"},{"key":"B2","doi-asserted-by":"publisher","first-page":"FSO61","DOI":"10.4155\/fso.15.61","article-title":"Lymphatic network in atherosclerosis: the underestimated path","volume":"1","author":"Milasan","year":"2015","journal-title":"Future Sci OA"},{"key":"B3","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1172\/JCI71610","article-title":"Lymphatic transport of high-density lipoproteins and chylomicrons","volume":"124","author":"Randolph","year":"2014","journal-title":"J Clin Invest"},{"key":"B4","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.cmet.2013.04.002","article-title":"Lymphatic vessels are essential for the removal of cholesterol from peripheral tissues by SR-BI-mediated transport of HDL","volume":"17","author":"Lim","year":"2013","journal-title":"Cell Metab"},{"key":"B5","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.tem.2016.12.002","article-title":"Cardiac lymphaticsa new avenue for therapeutics?","volume":"28","author":"Vuorio","year":"2017","journal-title":"Trends Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.atherosclerosis.2019.01.031","article-title":"Early rescue of lymphatic function limits atherosclerosis progression in Ldlr\u2212\/\u2212 mice","volume":"283","author":"Milasan","year":"2019","journal-title":"Atherosclerosis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e58376","DOI":"10.7554\/eLife.58376","article-title":"Lymphangiogenic therapy prevents cardiac dysfunction by ameliorating inflammation and hypertension","volume":"9","author":"Song","year":"2020","journal-title":"eLife"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e006892","DOI":"10.1161\/JAHA.117.006892","article-title":"Apolipoprotein A-I modulates atherosclerosis through lymphatic vessel-dependent mechanisms in mice","volume":"6","author":"Milasan","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1172\/JCI171582","article-title":"The emerging importance of lymphatics in health and disease: an NIH workshop report","volume":"133","author":"Mehrara","year":"2023","journal-title":"J Clin Invest"},{"key":"B10","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1098\/rsif.2011.0751","article-title":"Modelling the lymphatic system: challenges and opportunities","volume":"9","author":"Margaris","year":"2012","journal-title":"J R Soc Interface"},{"key":"B11","doi-asserted-by":"publisher","first-page":"627647","DOI":"10.3389\/fcell.2020.627647","article-title":"Molecular mechanisms controlling lymphatic endothelial junction integrity","volume":"8","author":"Norden","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1016\/j.ajpath.2012.02.019","article-title":"Plasticity of button-like junctions in the endothelium of airway lymphatics in development and inflammation","volume":"180","author":"Yao","year":"2012","journal-title":"Am J Pathol"},{"key":"B13","article-title":"Anatomy, lymphatic system","volume-title":"StatPearls","author":"Null","year":"2025"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.3390\/ijms26031364","article-title":"Atherosclerosis: a comprehensive review of molecular factors and mechanisms","volume":"26","author":"Tasouli-Drakou","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B15","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/joim.12406","article-title":"Inflammation and plaque vulnerability","volume":"278","author":"Hansson","year":"2015","journal-title":"J Intern Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.2967\/jnumed.107.038661","article-title":"Role of inflammation in atherosclerosis","volume":"48","author":"Spagnoli","year":"2007","journal-title":"J Nucl Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"707","DOI":"10.3390\/cells12050707","article-title":"Hypotheses on atherogenesis triggering: does the infectious nature of atherosclerosis development have a substruction?","volume":"12","author":"Lusta","year":"2023","journal-title":"Cells"},{"key":"B18","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1161\/CIRCRESAHA.115.306301","article-title":"Endothelial cell dysfunction and the pathobiology of atherosclerosis","volume":"118","author":"Gimbrone","year":"2016","journal-title":"Circ Res"},{"key":"B19","first-page":"469","article-title":"Nitric oxide and superoxide in inflammation and immune regulation","volume":"54","author":"Guzik","year":"2003","journal-title":"J Physiol Pharmacol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1056\/NEJMoa0906431","article-title":"Cardiac-resynchronization therapy for the prevention of heart-failure events","volume":"361","author":"Moss","year":"2009","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1134\/S0006297916110134","article-title":"The role of cytokines in the development of atherosclerosis","volume":"81","author":"Fatkhullina","year":"2016","journal-title":"Biochem Biokhimiia"},{"key":"B22","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3389\/fimmu.2019.00308","article-title":"Inflammation and lymphatic function","volume":"10","author":"Schwager","year":"2019","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10456-014-9416-7","article-title":"Inflammation-induced lymphangiogenesis and lymphatic dysfunction","volume":"17","author":"Liao","year":"2014","journal-title":"Angiogenesis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41392-025-02249-0","article-title":"Vascular endothelial growth factor signaling in health and disease: from molecular mechanisms to therapeutic perspectives","volume":"10","author":"Lee","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B25","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3390\/ijms14010088","article-title":"The role of the VEGF-C\/VEGFRs axis in tumor progression and therapy","volume":"14","author":"Chen","year":"2012","journal-title":"Int J Mol Sci"},{"key":"B26","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/biomedicines13010006","article-title":"Vascular endothelial growth factor (VEGF) family and the immune system: activators or inhibitors?","volume":"13","author":"Failla","year":"2024","journal-title":"Biomedicines"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1002\/sctm.19-0241","article-title":"Mesenchymal stromal cells pretreated with pro-inflammatory cytokines promote skin wound healing through VEGFC-mediated angiogenesis","volume":"9","author":"Zhu","year":"2020","journal-title":"Stem Cells Transl Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"8413","DOI":"10.1074\/jbc.273.14.8413","article-title":"Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C","volume":"273","author":"Ristim\u00e4ki","year":"1998","journal-title":"J Biol Chem"},{"key":"B29","doi-asserted-by":"publisher","first-page":"387842","DOI":"10.1155\/2015\/387842","article-title":"Proinflammatory cytokines increase vascular endothelial growth factor expression in alveolar epithelial cells","volume":"2015","author":"Maloney","year":"2015","journal-title":"Mediators Inflamm"},{"key":"B30","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1089\/lrb.2008.1008","article-title":"The lymphatic system in health and disease","volume":"6","author":"Cueni","year":"2008","journal-title":"Lymphat Res Biol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"4843","DOI":"10.1128\/MCB.02214-07","article-title":"Deletion of vascular endothelial growth factor C (VEGF-C) and VEGF-D is not equivalent to VEGF receptor 3 deletion in mouse embryos","volume":"28","author":"Haiko","year":"2008","journal-title":"Mol Cell Biol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.cell.2010.01.045","article-title":"Lymphangiogenesis: molecular mechanisms and future promise","volume":"140","author":"Tammela","year":"2010","journal-title":"Cell"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1172\/JCI72189","article-title":"VEGF-C\u2013dependent stimulation of lymphatic function ameliorates experimental inflammatory bowel disease","volume":"124","author":"D\u2019Alessio","year":"2014","journal-title":"J Clin Invest"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1093\/cvr\/cvaa291","article-title":"The physiological and pathological functions of VEGFR3 in cardiac and lymphatic development and related diseases","volume":"117","author":"Monaghan","year":"2020","journal-title":"Cardiovasc Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.cell.2020.06.039","article-title":"The lymphatic vasculature in the 21st century: novel functional roles in homeostasis and disease","volume":"182","author":"Oliver","year":"2020","journal-title":"Cell"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1089\/ars.2005.7.1744","article-title":"The role of endothelial cells in the resolution of acute inflammation","volume":"7","author":"Kadl","year":"2005","journal-title":"Antioxid Redox Signal"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.3390\/cells10061344","article-title":"Leukocyte trafficking via lymphatic vessels in atherosclerosis","volume":"10","author":"Yeo","year":"2021","journal-title":"Cells"},{"key":"B38","doi-asserted-by":"publisher","first-page":"182","DOI":"10.4110\/in.2014.14.4.182","article-title":"Interplay between inflammatory responses and lymphatic vessels","volume":"14","author":"Shin","year":"2014","journal-title":"Immune Netw"},{"key":"B39","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1021\/acsptsci.9b00075","article-title":"New advances in targeting the resolution of inflammation: implications for specialized pro-resolving mediator GPCR drug discovery","volume":"3","author":"Park","year":"2020","journal-title":"ACS Pharmacol Transl Sci"},{"key":"B40","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.jacc.2021.11.048","article-title":"Immune checkpoint therapies and atherosclerosis: mechanisms and clinical implications: JACC state-of-the-art review","volume":"79","author":"Vuong","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/j.jacc.2018.08.2147","article-title":"Macrophage trafficking, inflammatory resolution, and genomics in atherosclerosis: JACC macrophage in CVD series (part 2)","volume":"72","author":"Moore","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1056\/NEJMra2000317","article-title":"Atherosclerotic plaque healing","volume":"383","author":"Vergallo","year":"2020","journal-title":"N Engl J Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"eabc2697","DOI":"10.1126\/sciadv.abc2697","article-title":"Efficient aortic lymphatic drainage is necessary for atherosclerosis regression induced by ezetimibe","volume":"6","author":"Yeo","year":"2020","journal-title":"Sci Adv"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.12688\/f1000research.14803.1","article-title":"Recent advances in understanding lymphangiogenesis and metabolism","volume":"7","author":"Lee","year":"2018","journal-title":"F1000Res"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1465816","DOI":"10.3389\/fendo.2024.1465816","article-title":"The role of vascular and lymphatic networks in bone and joint homeostasis and pathology","volume":"15","author":"Huang","year":"2024","journal-title":"Front Endocrinol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1172\/JCI63685","article-title":"Lymphatic vasculature mediates macrophage reverse cholesterol transport in mice","volume":"123","author":"Martel","year":"2013","journal-title":"J Clin Invest"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1161\/ATVBAHA.114.302528","article-title":"Lymphatic vessel insufficiency in hypercholesterolemic mice alters lipoprotein levels and promotes atherogenesis","volume":"34","author":"Vuorio","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"104351","DOI":"10.1016\/j.jaccas.2025.104351","article-title":"Anti-VEGF therapy-induced accelerated atherosclerosis: STEMI in a young adult","volume":"30","author":"Byer","year":"2025","journal-title":"JACC Case Rep"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1016\/j.ijcard.2013.03.010","article-title":"Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis\u2013implications for cardiovascular safety","volume":"168","author":"Winnik","year":"2013","journal-title":"Int J Cardiol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1161\/CIRCRESAHA.120.317186","article-title":"Arterial delivery of VEGF-C stabilizes atherosclerotic lesions","volume":"128","author":"Silvestre-Roig","year":"2021","journal-title":"Circ Res"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1038\/mt.2009.70","article-title":"VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial","volume":"17","author":"Stewart","year":"2009","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1172\/JCI20465","article-title":"VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment","volume":"113","author":"Cursiefen","year":"2004","journal-title":"J Clin Invest"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1412857","DOI":"10.3389\/fcvm.2024.1412857","article-title":"Targeting lymphatic function in cardiovascular-kidney-metabolic syndrome: preclinical methods to analyze lymphatic function and therapeutic opportunities","volume":"11","author":"Fowler","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"12677","DOI":"10.1073\/pnas.221449198","article-title":"A model for gene therapy of human hereditary lymphedema","volume":"98","author":"Karkkainen","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B55","doi-asserted-by":"publisher","first-page":"e23879","DOI":"10.1096\/fj.202400160RR","article-title":"The interplay between lymphatic vessels and macrophages in inflammation response","volume":"38","author":"Zhou","year":"2024","journal-title":"FASEB J"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1096\/fj.02-0401fje","article-title":"Therapeutic lymphangiogenesis with human recombinant VEGF-C","volume":"16","author":"Szuba","year":"2002","journal-title":"FASEB J"},{"key":"B57","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1084\/jem.20020587","article-title":"Lymphangiogenic gene therapy with minimal blood vascular side effects","volume":"196","author":"Saaristo","year":"2002","journal-title":"J Exp Med"},{"key":"B58","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s10456-015-9469-2","article-title":"VEGF-C and VEGF-C156S in the pro-lymphangiogenic growth factor therapy of lymphedema: a large animal study","volume":"18","author":"Visuri","year":"2015","journal-title":"Angiogenesis"},{"key":"B59","doi-asserted-by":"publisher","first-page":"100816","DOI":"10.1016\/j.jhepr.2023.100816","article-title":"Recombinant VEGF-C (Cys156Ser) improves mesenteric lymphatic drainage and gut immune surveillance in experimental cirrhosis","volume":"5","author":"Juneja","year":"2023","journal-title":"JHEP Rep"},{"key":"B60","doi-asserted-by":"publisher","first-page":"123410","DOI":"10.1016\/j.biomaterials.2025.123410","article-title":"LNPs-mediated VEGF-C mRNA delivery promotes heart repair and attenuates inflammation by stimulating lymphangiogenesis post-myocardial infarction","volume":"322","author":"Zhang","year":"2025","journal-title":"Biomaterials"},{"key":"B61","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1172\/JCI15830","article-title":"VEGF-C gene therapy augments postnatal lymphangiogenesis and ameliorates secondary lymphedema","volume":"111","author":"Yoon","year":"2003","journal-title":"J Clin Invest"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/j.bjps.2020.05.009","article-title":"Phase 1 Lymfactin\u24c7 study: short-term safety of combined adenoviral VEGF-C and lymph node transfer treatment for upper extremity lymphedema","volume":"73","author":"Hartiala","year":"2020","journal-title":"J Plast Reconstr Aesthetic Surg"},{"key":"B63","doi-asserted-by":"publisher","first-page":"256e","DOI":"10.1097\/PRS.0000000000011675","article-title":"Phase II study shows the effect of adenoviral vascular endothelial growth factor C and lymph node transfer in lymphedema","volume":"155","author":"Rannikko","year":"2025","journal-title":"Plast Reconstr Surg"},{"key":"B64","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1373\/clinchem.2010.155333","article-title":"HDL Measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events","volume":"57","author":"Rosenson","year":"2011","journal-title":"Clin Chem"},{"key":"B65","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1080\/10409238.2021.1925217","article-title":"Cholesterol efflux pathways, inflammation, and atherosclerosis","volume":"56","author":"Groenen","year":"2021","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.3390\/cancers11081097","article-title":"Apolipoprotein A-I (ApoA-I), immunity, inflammation and cancer","volume":"11","author":"Georgila","year":"2019","journal-title":"Cancers"},{"key":"B67","doi-asserted-by":"publisher","first-page":"e33917","DOI":"10.1371\/journal.pone.0033917","article-title":"Apolipoprotein A-I attenuates palmitate-mediated NF-\u03baB activation by reducing toll-like receptor-4 recruitment into lipid rafts","volume":"7","author":"Cheng","year":"2012","journal-title":"PLoS One"},{"key":"B68","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jacbts.2024.11.001","article-title":"Apolipoprotein A1 (CSL112) increases lecithin-cholesterol acyltransferase levels in HDL particles and promotes reverse cholesterol transport","volume":"10","author":"Mathias","year":"2025","journal-title":"JACC Basic Transl Sci"},{"key":"B69","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1161\/ATVBAHA.114.303720","article-title":"CSL112 Enhances biomarkers of reverse cholesterol transport after single and multiple infusions in healthy subjects","volume":"34","author":"Gille","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.1093\/eurheartj\/ehae614","article-title":"Apolipoprotein A-I infusions and cardiovascular outcomes in acute myocardial infarction according to baseline LDL-cholesterol levels: the AEGIS-II trial","volume":"45","author":"Gibson","year":"2024","journal-title":"Eur Heart J"},{"key":"B71","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1001\/jama.290.17.2292","article-title":"Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial","volume":"290","author":"Nissen","year":"2003","journal-title":"JAMA"},{"key":"B72","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1001\/jamacardio.2018.2112","article-title":"Effect of infusion of high-density lipoprotein mimetic containing recombinant apolipoprotein A-I Milano on coronary disease in patients with an acute coronary syndrome in the MILANO-PILOT trial: a randomized clinical trial","volume":"3","author":"Nicholls","year":"2018","journal-title":"JAMA Cardiol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1001\/jamacardio.2018.2121","article-title":"Effect of serial infusions of CER-001, a Pre-\u03b2 high-density lipoprotein mimetic, on coronary atherosclerosis in patients following acute coronary syndromes in the CER-001 atherosclerosis regression acute coronary syndrome trial","volume":"3","author":"Nicholls","year":"2018","journal-title":"JAMA Cardiol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"9582430","DOI":"10.1155\/2016\/9582430","article-title":"Macrophages and their role in atherosclerosis: pathophysiology and transcriptome analysis","volume":"2016","author":"Bobryshev","year":"2016","journal-title":"BioMed Res Int"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1430236","DOI":"10.3389\/fphar.2024.1430236","article-title":"NLRP3 Inflammasome in atherosclerosis: mechanisms and targeted therapies","volume":"15","author":"Chen","year":"2024","journal-title":"Front Pharmacol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"8162","DOI":"10.3390\/ijms24098162","article-title":"Portrayal of NLRP3 inflammasome in atherosclerosis: current knowledge and therapeutic targets","volume":"24","author":"Tanase","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"B78","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Ridker","year":"2021","journal-title":"Lancet Lond Engl"},{"key":"B79","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jjcc.2023.05.006","article-title":"Efficacy and safety of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan (RESCUE-2): a randomized, double-blind, placebo-controlled, phase 2 trial","volume":"82","author":"Wada","year":"2023","journal-title":"J Cardiol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"e138","DOI":"10.1093\/cvr\/cvab231","article-title":"From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction?","volume":"117","author":"Ridker","year":"2021","journal-title":"Cardiovasc Res"},{"key":"B81","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/art.40366","article-title":"Association of tumor necrosis factor inhibitor treatment with reduced indices of subclinical atherosclerosis in patients with psoriatic disease","volume":"70","author":"Eder","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"e26430","DOI":"10.7759\/cureus.26430","article-title":"Tumor necrosis factor-alpha inhibitors and cardiovascular risk in rheumatoid arthritis: a systematic review","volume":"14","author":"Nair","year":"2022","journal-title":"Cureus"},{"key":"B83","doi-asserted-by":"publisher","first-page":"88043","DOI":"10.18632\/oncotarget.21408","article-title":"Inhibition of IL-8-mediated endothelial adhesion, VSMCs proliferation and migration by siRNA-TMEM98 suggests TMEM98\u2019s emerging role in atherosclerosis","volume":"8","author":"Lv","year":"2017","journal-title":"Oncotarget"},{"key":"B84","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1089\/lrb.2021.0026","article-title":"The role of lymphangiogenesis in coronary atherosclerosis","volume":"20","author":"Feng","year":"2022","journal-title":"Lymphat Res Biol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"495","DOI":"10.3390\/jcm8040495","article-title":"Arterial lymphatics in atherosclerosis: old questions, new insights, and remaining challenges","volume":"8","author":"Cs\u00e1nyi","year":"2019","journal-title":"J Clin Med"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.3390\/cells10081869","article-title":"HDL In atherosclerotic cardiovascular disease: in search of a role","volume":"10","author":"Casula","year":"2021","journal-title":"Cells"},{"key":"B87","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1096\/fj.201500112","article-title":"Phenotypic transformation of intimal and adventitial lymphatics in atherosclerosis: a regulatory role for soluble VEGF receptor 2","volume":"30","author":"Taher","year":"2016","journal-title":"FASEB J"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1093\/eurheartj\/ehu203","article-title":"Anti-inflammatory therapies for cardiovascular disease","volume":"35","author":"Ridker","year":"2014","journal-title":"Eur Heart J"},{"key":"B89","doi-asserted-by":"publisher","first-page":"e3000704","DOI":"10.1371\/journal.pbio.3000704","article-title":"Single-cell mapping reveals new markers and functions of lymphatic endothelial cells in lymph nodes","volume":"18","author":"Fujimoto","year":"2020","journal-title":"PLoS Biol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1172\/JCI73316","article-title":"Emerging roles of lymphatic endothelium in regulating adaptive immunity","volume":"124","author":"Card","year":"2014","journal-title":"J Clin Invest"},{"key":"B91","doi-asserted-by":"publisher","first-page":"476","DOI":"10.3389\/fphys.2020.00476","article-title":"Extracellular vesicles as potential prognostic markers of lymphatic dysfunction","volume":"11","author":"Milasan","year":"2020","journal-title":"Front Physiol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1172\/JCI71612","article-title":"Emerging lymphatic imaging technologies for mouse and man","volume":"124","author":"Sevick-Muraca","year":"2014","journal-title":"J Clin Invest"},{"key":"B93","doi-asserted-by":"publisher","first-page":"e220231","DOI":"10.1148\/radiol.220231","article-title":"Imaging and interventions for lymphatic and lymphatic-related disorders","volume":"307","author":"Benjamin","year":"2023","journal-title":"Radiology"},{"key":"B94","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.addr.2020.08.013","article-title":"Imaging technology of the lymphatic system","volume":"170","author":"Polomska","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"key":"B95","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1097\/RLI.0000000000000966","article-title":"Back to the future II-A comprehensive update on the rapidly evolving field of lymphatic imaging and interventions","volume":"58","author":"Pieper","year":"2023","journal-title":"Invest Radiol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1132097","DOI":"10.3389\/fphys.2023.1132097","article-title":"Imaging peripheral lymphatic dysfunction in chronic conditions","volume":"14","author":"Sevick-Muraca","year":"2023","journal-title":"Front Physiol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1177\/2047487318773384","article-title":"Interplay between hypercholesterolaemia and inflammation in atherosclerosis: translating experimental targets into clinical practice","volume":"25","author":"Tu\u00f1\u00f3n","year":"2018","journal-title":"Eur J Prev Cardiol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.pharmthera.2018.08.012","article-title":"Interactions between dyslipidemia and the immune system and their relevance as putative therapeutic targets in atherosclerosis","volume":"193","author":"Lacy","year":"2019","journal-title":"Pharmacol Ther"},{"key":"B99","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1080\/14728222.2024.2362644","article-title":"New targets and mechanisms of action for lipid-lowering and anti-inflammatory therapies in atherosclerosis: where does the field stand?","volume":"28","author":"Nicholls","year":"2024","journal-title":"Expert Opin Ther Targets"},{"key":"B100","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.2174\/0109298673311105240902053715","article-title":"Lipids and inflammation: novel molecular targets and therapeutic implications","volume":"32","author":"Triglia","year":"2025","journal-title":"Curr Med Chem"},{"key":"B101","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.atherosclerosis.2013.02.028","article-title":"Interactions between inflammation and lipid metabolism: relevance for efficacy of anti-inflammatory drugs in the treatment of atherosclerosis","volume":"228","author":"van Diepen","year":"2013","journal-title":"Atherosclerosis"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1774468\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T05:34:57Z","timestamp":1773812097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1774468\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":101,"alternative-id":["10.3389\/fcvm.2026.1774468"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1774468","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"article-number":"1774468"}}